This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending December 31, 2023
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
IR Contacts
Headquarters
Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080
Investor Relations
Sutro Biopharma
Emily White
Executive Director, Investor Relations and Communications
T: 650-823-7681
ewhite@sutrobio.com